https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(06)68175-0.pdf

Guillain-Barré syndrome

https://thelancet.com/pdfs/journals/lancet/PIIS0140-6736(16)00339-1.pdf

Guillain-Barré syndrome.

The Guillain–Barre syndrome is the most frequent cause of acute flaccid paralysis worldwide and constitutes a neurologic emergency. This review considers the current understanding, diagnosis, and management of the syndrome.

https://www.nejm.org/doi/pdf/10.1056/NEJMra1114525?articleTools=true

Guillain–Barré Syndrome

Guillain-Barre syndrome (GBS) is a potentially life-threatening postinfectious disease characterized by rapidly progressive, symmetrical weakness of the extremities About 25% of patients develop respiratory insufficiency and many show signs of autonomic dysfunction Diagnosis can usually be made on clinical grounds, but lumbar puncture and electrophysiological studies can help to substantiate the diagnosis and to differentiate demyelinating from axonal subtypes of GBS Molecular mimicry of pathogen-borne antigens, leading to generation of crossreactive antibodies that also target gangliosides, is part of the pathogenesis of GBS; the subtype and severity of the syndrome are partly determined by the nature of the antecedent infection and specificity of such antibodies Intravenous immunoglobulin and plasma exchange are proven effective treatments but many patients have considerable residual deficits Discrimination of patients with treatment-related fluctuations from those with acute-onset chronic inflammatory demyelinating polyneuropathy is important, as these conditions may require different treatments Novel prognostic models can accurately predict outcome and the need for artificial ventilation, which could aid the selection of patients with a poor prognosis for more-individualized care This Review summarizes the clinical features of and diagnostic criteria for GBS, and discusses its pathogenesis, treatment and prognosis

Guillain–Barré syndrome: pathogenesis, diagnosis, treatment and prognosis

Population incidence of Guillain-Barre syndrome (GBS) is required to assess changes in GBS epidemiology, but published estimates of GBS incidence vary greatly depending on case ascertainment, definiti

/pdf/population-incidence-of-guillain-barre-syndrome-a-systematic-3smew7p11a.pdf

Population incidence of Guillain-Barré syndrome: a systematic review and meta-analysis.

https://zenodo.org/record/1259431/files/article.pdf

Guillain-Barré syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data.

Applicability of the Brighton Collaboration Case Definition for seizure after immunization in active and passive surveillance in Canada.

Guillain-Barre syndrome (GBS) cases admitted to Canadian pediatric tertiary care centers were ascertained through active surveillance. From 1996 to 2012, 246 cases were identified, and 24 (10%) had onset ≤30 days after immunization. Annual rate of postimmunization GBS was 2.0 per 100,000 hospitalizations. Postimmunization GBS was an infrequent cause of pediatric hospitalization.

Barbara J. Law

Papers

Guillain-Barré syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data.

Applicability of the Brighton Collaboration Case Definition for seizure after immunization in active and passive surveillance in Canada.

Guillain-BarrÉ Syndrome After Immunization in Canadian Children (1996-2012).